HDCN-- Consequences of Hyperphosphatemia: Are We Accepting the Unacceptable? -- Satellite Symposium, American Society of Nephrology Annual Scientific Meeting, Miami, November, 1999.

	Online Slide/Audio Symposium






Satellite Symposium of the American Society of Nephrology 32nd Annual Scientific Meeting, November, 1999 Genzyme Therapeutics, ASN Corporate Sponsor Supported by an unrestricted grant from Genzyme Therapeutics Consequences of Hyperphosphatemia: Are We Accepting the Unacceptable?

You need to REGISTER WITH HDCN (it's free) before you can access these talks. This program offers 1.5 hours of Category One CME Credit through the University of Minnesota. For CME-related information click here


The Talks

Role of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism
Eduardo Slatopolsky, M.D.

Acid-Base and the Skeleton
David Bushinsky, M.D.

Epidemiology and Quality Improvement in Phosphate Management
Glenn Chertow, M.D., M.P.H.

Questions and Answers
Drs. Slatopolsky, Bushinsky, and Chertow

Selected References
Compiled by course faculty

For more information, please see the 1998 ASN Satellite Symposium on Hyperphosphatemia. click here

Faculty

David Bushinsky, M.D., Professor of Medicine, Pharmacology, and Physiology; Chief, Nephrology Unit, University of Rochester Medical Center, Rochester, NY.

Glenn Chertow, M.D., M.P.H. Professor of Medicine, University of California at San Francisco, San Francisco, CA.

Eduardo Slatopolsky, M.D., Professor of Renal Diseases in Medicine, Washington University, St. Louis, MO

Back to symposia list by topic
Back to symposia list by meeting
Back to HDCN home page